
Types of Schizophrenia
The DSM-5 no longer recognizes schizophrenia subtypes as separate diagnostic categories. However, the five classical subtypes (paranoid, hebephrenic, undifferentiated, residual, and catatonic) can still be helpful as specifiers for treatment planning.
Schizophrenia affects approximately 1% of people in the United States, with men typically receiving a diagnosis in their late teens to early 20s and women typically receiving a diagnosis in their late 20s to early 30s.
When schizophrenia occurs in children (which is rare), symptoms in older children and teens can include social withdrawal, sleep disruptions, impaired school performance, irritability, irregular behavior, and substance use.
Schizophrenia is a chronic mental health disorder that affects:
emotions
the ability to think rationally and clearly
the ability to interact with and relate to others
The National Alliance on Mental Illness (NAMI) reports that research indicates that schizophrenia affects close to 1% of people in the United States. Men typically receive a schizophrenia diagnosis in their late teens to early 20s. Women typically receive a diagnosis in their late 20s to early 30s.
Episodes of the illness can come and go, similar to the process of remission. When there's an 'active' period, an individual might experience:
Current DSM-5 status
Diagnostic changes were made for several disorders in the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, text revision (DSM-5-TR), including schizophrenia. In the past, an individual only had to have one of the symptoms to receive a confirmed diagnosis Now, a person must have at least two of the symptoms.
The DSM-5 also removed the subtypes as separate diagnostic categories, based on the presenting symptom. This was found to not be helpful, since many subtypes overlapped with one another and were thought to decrease the diagnostic validity, according to the American Psychiatric Association (APA).
Instead, these subtypes are now specifiers for the overarching diagnosis, to provide more detail for the clinician.
Subtypes of schizophrenia
Although the subtypes don't exist as separate clinical disorders anymore, they can still be helpful as specifiers and for treatment planning. There are five classical subtypes:
paranoid
hebephrenic
undifferentiated
residual
catatonic
Paranoid schizophrenia
In 2013, the APA determined that paranoia was a positive symptom of the disorder. Paranoid schizophrenia was no longer considered a separate condition.
However, the subtype description is still used because of how common this symptom is. Symptoms include:
delusions
hallucinations
disorganized speech (word salad, echolalia)
trouble concentrating
behavioral impairment (impulse control challenges, emotional lability)
flat affect
Hebephrenic (disorganized) schizophrenia
Hebephrenic or disorganized schizophrenia is still recognized by the International Statistical Classification of Diseases and Related Health Problems (ICD-10), although it's been removed from the DSM-5-TR.
In this variation of schizophrenia, the individual does not have hallucinations or delusions. Instead, they experience disorganized behavior and speech. This can include:
flat affect (inability to display emotions)
speech disturbances
disorganized thinking
involuntary or unexpected emotions or facial reactions
trouble with daily activities
Undifferentiated schizophrenia
Undifferentiated schizophrenia was the term used to describe when an individual displayed behaviors that were applicable to more than one type of schizophrenia. For instance, an individual who had catatonic behavior but also had delusions or hallucinations and disorganized speech might have received a diagnosis of undifferentiated schizophrenia.
With the new diagnostic criteria, this merely signifies to the clinician that a variety of symptoms are present.
Residual schizophrenia
This 'subtype' is a bit tricky. It's been used when a person has a previous diagnosis of schizophrenia but no longer has any prominent symptoms of the disorder. The symptoms have generally lessened in intensity.
Residual schizophrenia usually includes more 'negative' than positive symptoms, such as:
flattened affect
psychomotor difficulties
slowed speech
limited attentiveness to personal hygiene
Many people with schizophrenia go through periods where their symptoms wax and wane (increase and decrease) and vary in frequency and intensity. Therefore, this designation is rarely used anymore.
Catatonic schizophrenia
Although catatonic schizophrenia had been listed as a subtype in the first Diagnostic and Statistical Manual of Mental Disorders first edition (1952) through the DSM-4 (1994), the DSM-5 removed it as a subtype. Catatonia is now considered a specifier. This is because it occurs in a variety of psychiatric and general medical conditions.
Catatonic schizophrenia typically presents itself as immobility, but it can also look like:
mimicking behavior
mutism (inability to speak)
a stupor-like condition (reduced responsiveness)
Childhood schizophrenia
Childhood schizophrenia isn't a subtype but rather an indicator of the time of diagnosis. A diagnosis in children is fairly uncommon.
When it does occur, it can be severe. Early onset schizophrenia typically occurs between ages 13 and 18 years. A diagnosis under age 13 years is considered very early onset and is extremely rare.
Symptoms in very young children are similar to those of developmental disorders, such as autism and attention deficit hyperactivity disorder (ADHD). These symptoms can include:
language delays
late or unusual crawling or walking
irregular motor movements
It's important to rule out developmental issues when considering a very early onset schizophrenia diagnosis.
Symptoms in older children and teens include:
social withdrawal
sleep disruptions
impaired school performance
irritability
irregular behavior
substance use
Younger individuals are less likely to have delusions, but they're more likely to have hallucinations. As teens get older, more typical symptoms of schizophrenia — like those seen in adults — usually emerge.
It's important to have a knowledgeable professional make a diagnosis of childhood schizophrenia because it's so rare. It's crucial to rule out any other condition, including substance use or an organic medical issue.
A child psychiatrist with experience in childhood schizophrenia should lead the treatment team and discussions about its plan. Treatment typically involves a combination approach that can include:
Conditions related to schizophrenia
Schizoaffective disorder
Schizoaffective disorder is a separate and different condition from schizophrenia, but sometimes it gets lumped in with it. This disorder has elements of both schizophrenia and mood disorders.
Psychosis, which involves a loss of connection with reality, is often a component. Mood disorders can include either mania or depression.
Schizoaffective disorder is further classified into subtypes based on whether a person has only depressive episodes or whether they also have manic episodes with or without depression. Symptoms can include:
paranoid thoughts
delusions or hallucinations
trouble concentrating
depression
hyperactivity or mania
limited attentiveness to personal hygiene
appetite disturbance
sleep disruptions
social withdrawal
disorganized thinking or behavior
Diagnosis is typically made through a thorough physical exam, interview, and psychiatric evaluation. It's important to rule out any medical conditions or any other mental illnesses like bipolar disorder. Treatments include:
medications
group or individual therapy
practical life skills training
Other related conditions
Other related conditions to schizophrenia include:
delusional disorder
brief psychotic disorder
schizophreniform disorder
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
10 minutes ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
29 minutes ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know
Yahoo
an hour ago
- Yahoo
MrFluffyFriend Launches XXXXL Calming Dog Bed for Large and Anxious Dogs
Over 600,000 dogs sleep better already — now available in 48 inch (120cm) & 56 inch (140cm) with up to 60% off and free shipping on Image by MrFluffyFriend LOS ANGELES, July 27, 2025 (GLOBE NEWSWIRE) -- MrFluffyFriend, a fast-growing U.S. pet wellness brand known for its calming products, announces the launch of its XXXXL Calming Dog Bed, specially designed for large breeds and dogs prone to anxiety. The oversized beds, now available in 120cm and 140cm, offer unmatched comfort and emotional relief thanks to premium materials and calming features rooted in behavioral science. Made with ultra-soft vegan faux fur, deep orthopedic padding, and a raised rim for added head and neck support, the XXXXL Calming Bed creates a soothing nest-like environment that helps dogs feel safe, supported, and calm — especially during fireworks, thunderstorms, or when left home alone. 'We've helped over 600,000 dogs sleep better with our calming beds,' says a MrFluffyFriend spokesperson. 'Our community asked for something big enough for their Labradors, Golden Retrievers, Huskies — and we listened. This launch is all about showing that big dogs deserve big comfort, too.' According to veterinarians, over 70% of dogs experience anxiety at some point, which can lead to restlessness, whining, and destructive behavior. MrFluffyFriend's calming design mimics a mother's touch, helping to trigger the release of serotonin and reduce stress naturally. Key Features: Sizes: XXXL (48 in / 120 cm) and XXXXL (56 in / 140 cm) Raised rim for orthopedic support and security Ultra-soft faux fur mimics a mother's touch Machine washable cover + water-resistant, non-slip base Hypoallergenic and pet-safe materials Ideal for large breeds and multi-dog households The launch is accompanied by a limited-time offer of up to 60% off, free shipping across the U.S., and a 30-day risk-free trial, making it easier than ever for pet parents to try the product. Early feedback has been overwhelmingly positive, with customers praising the bed's luxurious size, fluffiness, and noticeable calming effect. Some report their dogs sleep longer, bark less, and even retreat to the bed during stressful moments like vet visits or fireworks. About MrFluffyFriend Founded with a mission to help pets feel safe, calm, and loved, MrFluffyFriend is a pet lifestyle brand trusted by dog lovers in over 25 countries. From calming beds to wellness accessories, every product is developed with science-backed design and premium materials to ensure pets thrive — emotionally and physically. Learn more at Media Contact: Thomas, H. info@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data